Clinical Trials
12 trialsNCT01042379 2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT03660826 2026-05-04
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04668300 2026-04-15
DOSa
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04705818 2026-03-06
CAIRE
Institut Bergonié
Phase 2 Completed
NCT04065269 2026-02-20
ATARI
Institute of Cancer Research, United Kingdom
Phase 2 Active not recruiting
NCT03851614 2026-02-09
DAPPER
University Health Network, Toronto
Phase 2 Active not recruiting
NCT02815995 2025-06-12
Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03912818 2023-09-11
Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer
Stanford University
Phase 2 Terminated
NCT03317457 2023-06-15
MEDISARC
AIO-Studien-gGmbH
Phase 2 Completed
NCT03798106 2023-06-12
A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma
Yonsei University
Phase 2 Completed
NCT03003520 2023-05-22
A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
Celgene
Phase 2 Completed
NCT02423863 2020-12-17
Poly-ICLC
Oncovir, Inc.
Phase 2 Completed